Login to Your Account



Shield Raises $13.9M, Gains Phase II Candidate from MRC

By Nuala Moran
Staff Writer

Wednesday, March 7, 2012
LONDON – Shield Therapeutics Ltd. signed an exclusive agreement with the UK Medical Research Council (MRC) for PT20, a treatment for hyperphosphatemia caused by kidney disease, and raised €10.5 million (US$13.9 million) for the onward development of the compound, which is ready for Phase II.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription